---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-098123"
form_type: "8-K"
ticker: "ESLA"
cik: "0001844417"
company_name: "Estrella Immunopharma, Inc."
filed_at: "2026-09-08T21:25:14+00:00"
generated_at: "2026-09-08T21:26:11.040460+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Estrella Immunopharma receives Nasdaq delisting notice for MVLS below $35M

## Summary
- Nasdaq letter Sept 1, 2026: MVLS below $35M for 30 straight business days (Jul 21-Aug 31, 2026).
- Also fails alternative standards: stockholders' equity <$2.5M, net income <$500k.
- Compliance period until Mar 1, 2027; must hit $35M MVLS for 10 consecutive days.
- Common stock continues trading on Nasdaq Capital Market under ESLA; no immediate effect.
- Company to monitor MVLS and evaluate options; no assurance of regaining compliance.

## SEC filing metadata
- accession: 0001213900-26-098123
- form_type: 8-K
- ticker: ESLA
- cik: 0001844417
- company_name: Estrella Immunopharma, Inc.
- filed_at: 2026-09-08T21:25:14+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1844417/000121390026098123/0001213900-26-098123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1844417/000121390026098123/ea030490301-8k_estrella.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-098123
- JSON: https://secwatch.observer/filing/0001213900-26-098123.json
- Plain text: https://secwatch.observer/filing/0001213900-26-098123.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.